TherapeuticsMD (NASDAQ:TXMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Saturday.
According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
Other equities research analysts have also issued reports about the company. Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a report on Wednesday, December 20th. Oppenheimer set a $10.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, December 20th. Deutsche Bank set a $9.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, December 20th. Jefferies Group restated a “buy” rating and issued a $15.00 target price on shares of TherapeuticsMD in a report on Tuesday, September 26th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $31.00 target price on shares of TherapeuticsMD in a report on Wednesday, November 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $14.50.
TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Monday, November 6th. The company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The firm had revenue of $4.42 million during the quarter, compared to analyst estimates of $5.36 million. During the same period in the previous year, the company earned ($0.13) EPS. The company’s revenue for the quarter was down 19.7% on a year-over-year basis. analysts expect that TherapeuticsMD will post -0.37 EPS for the current fiscal year.
In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of the business’s stock in a transaction dated Friday, December 8th. The stock was bought at an average cost of $6.21 per share, for a total transaction of $31,050.00. Following the completion of the acquisition, the director now directly owns 3,555 shares in the company, valued at $22,076.55. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 23.92% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. lifted its holdings in shares of TherapeuticsMD by 3.9% during the second quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after buying an additional 818 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of TherapeuticsMD by 7.2% during the second quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after buying an additional 1,322 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of TherapeuticsMD by 6.5% during the second quarter. Legal & General Group Plc now owns 56,234 shares of the company’s stock worth $298,000 after buying an additional 3,441 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of TherapeuticsMD by 3.4% during the second quarter. The Manufacturers Life Insurance Company now owns 123,580 shares of the company’s stock worth $651,000 after buying an additional 4,058 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of TherapeuticsMD by 3.5% during the second quarter. Rhumbline Advisers now owns 183,408 shares of the company’s stock worth $967,000 after buying an additional 6,232 shares during the last quarter. Institutional investors own 73.69% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “TherapeuticsMD (TXMD) Stock Rating Upgraded by Zacks Investment Research” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.com-unik.info/2018/01/20/therapeuticsmd-txmd-stock-rating-upgraded-by-zacks-investment-research.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.